Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the combination of weekly oxaliplatin × 4, weekly irinotecan × 4 and capecitabine Monday through Friday for 4 weeks of every 6 week cycle in patients with solid tumors; to determine the pharmacokinetic profile...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Chemother Pharmacol
Glavni autori: Krishnamurthi, Smitha S., Brell, Joanna M., Hoppel, Charles L., Egorin, Merrill J., Weaver, Karen C., Li, Xiaolin, Ingalls, Stephen T., Zuhowski, Eleanor G., Schluchter, Mark D., Dowlati, Afshin, Cooney, Matthew M., Gibbons, Joseph, Overmoyer, Beth A., Ivy, S. Percy, Remick, Scot C.
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4788493/
https://ncbi.nlm.nih.gov/pubmed/18414865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0754-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items